Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry Rogers • 19 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the risk of opportunistic infections during ibrutinib treatment for B-cell malignancies, including chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Kerry Rogers

The potential role of therapies targeting surface antigens in the CLL treatment landscape 1:48
The potential role of therapies targeting surface antigens in the CLL treatment landscape
Kerry Rogers • 13 Sep 2025
Improving the targeting of surface antigens in CLL: moving beyond monoclonal antibodies 4:20
Improving the targeting of surface antigens in CLL: moving beyond monoclonal antibodies
Kerry Rogers • 13 Sep 2025
The management of double-refractory CLL: current options and approaches being explored 3:04
The management of double-refractory CLL: current options and approaches being explored
Kerry Rogers • 13 Sep 2025
Key updates in hairy cell leukemia from ASH 2024 5:12
Key updates in hairy cell leukemia from ASH 2024
Kerry Rogers • 9 Dec 2024

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals